CUVITRU 200 mg/mL
Immune Globulin Subcutaneous (Human) · INJECTION, SOLUTION · Takeda Pharmaceuticals America, Inc.
CUVITRU is a injection, solution containing immune globulin subcutaneous (human) at 200 mg/mL, taken subcutaneous. Manufactured by Takeda Pharmaceuticals America, Inc..
Key Facts
- Brand Name
- CUVITRU
- Generic Name
- Immune Globulin Subcutaneous (Human)
- NDC Code (Product)
0944-2850- Manufacturer
- Takeda Pharmaceuticals America, Inc.
- Strength
- 200 mg/mL
- Dosage Form
- INJECTION, SOLUTION
- Route
- SUBCUTANEOUS
- Marketing Status
- Application #
- BLA125596
- Marketing Start
- 10/18/2016
Recall History
No Recall HistoryFull Prescribing Information
Indications & Usage
Category V For the temporary relief of general cold and flu symptoms, fever, achiness, and cough.
Dosage & Administration
Category V Orally 25 drops, 2 times per day or as directed by a physician. Children 12 and under use one half the adult dosage.
Warnings
Category V Use only under the direction of a health care professional. Do not use if tamper evident seal is broken or missing.
Frequently Asked Questions
What is CUVITRU used for?
CUVITRU contains Immune Globulin Subcutaneous (Human). It is a injection, solution taken subcutaneous. Consult your doctor for specific uses.
Is CUVITRU a controlled substance?
CUVITRU is not classified as a controlled substance by the DEA.
What is the generic name for CUVITRU?
The generic name for CUVITRU is Immune Globulin Subcutaneous (Human). There are no other listed brand versions of Immune Globulin Subcutaneous (Human).
What is the NDC code for CUVITRU 200 mg/mL?
The NDC (National Drug Code) for CUVITRU 200 mg/mL is 0944-2850, listed by Takeda Pharmaceuticals America, Inc..
Not medical advice. Always consult your doctor or pharmacist before making any medication decisions.
Data from openFDA · Public domain (CC0 1.0)